Sustained release olanzapine formulations
US10646443B2 · kind B2 · utility
1Cited by
2References
58Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 20, 2018 |
| Grant date | May 12, 2020 |
| Priority date | — |
| Expiry date | Mar 20, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.